Stroke Biomarkers

Proteome Sciences PLC
29 July 2004

Proteome Sciences plc
PRESS RELEASE
For immediate release


                      PROTEOME SCIENCES' STROKE BIOMARKERS

Proteome Sciences plc ('the company') announces that, although the evaluation of
its stroke biomarkers is continuing to progress well, due to the need to further
evaluate recent data relating specifically to this research programme, Biosite
Incorporated ('Biosite') does not intend to include these markers on its first
generation stroke panel, which is currently under late-stage development.  These
issues are currently being addressed, and Biosite is continuing to evaluate the
markers for use on future generations of the panel, which may have extended
applications.

Gunars Valkirs, VP Biosite Discovery commented:

'Our collaborative work to date with Proteome Sciences reinforces our commitment
to continuing to work together.  We will continue to evaluate the Proteome
stroke markers for inclusion in future panels'.

Christopher Pearce, CEO, Proteome Sciences commented:

'The validation of the company's biomarkers for stroke continues to progress
well and the recent data presented at the 5th World Stroke Congress in
Vancouver, Canada in June clearly demonstrates the potential of our markers for
the early diagnosis of stroke, particularly within the most important 3 hour
window within which therapy must be started.  We remain confident that these
markers have strong utility for the development of rapid and accurate diagnostic
tests for a range of new applications and are pleased that Biosite continue to
work diligently to evaluate our markers for potential inclusion on their
point-of-care platform.

'We continue to progress discussions with other parties for licensing of the
company's stroke biomarkers for high-throughput, central laboratory testing
applications.  As noted in the Chairman's Statement in the 2003 Report and
Accounts, this sector accounts for over 90% of the total market, with POC
accounting for between 5% and 10%.

'A further update on general commercial progress will be given at the AGM on the
4th August, 2004.'

ENDS


For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive:
[e-mail]
James Malthouse, Finance Director:
[e-mail]

James Green, Commercial Director:               [e-mail]
Ian Pike, Business Development Director:        [e-mail]

Tel:                   [phone]

www.proteomics.com

Public Relations for Proteome Sciences

Ikon Associates

Adrian Shaw:
[e-mail]

Tel:                   [phone]
Mobile:                [phone]


Notes to Editors:

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications.  It has to date developed sensitive
blood assays for stroke, vCJD, BSE, solid organ transplant rejection and
Alzheimer's disease.

The main focus of its research currently addresses neurological,
neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions.
The process of commercialisation is being actively pursued across the portfolio
of the Company's programmes and to date licensing deals have been signed for the
commercialisation of tests for stroke and TSEs.

Proteome Sciences is headquartered in Cobham, Surrey in the UK and has
laboratories at King's College Hospital, London and in Frankfurt.  It employs 40
full time scientists, in addition to its corporate and business development
staff.  The Company is listed on the Alternative Investment Market.


                      This information is provided by RNS
            The company news service from the London Stock Exchange